Dan Soffer

#OriginalResearch Both 'weekend warrior' and regular exercise patterns lower cardiometabolic risk. The total volume of physical activity, rather the pattern is most relevant for risk of future disease. @ShinoKany @shaan_khurshid ahajournals.org/doi/abs/10.116…

A timely symposium on Racial Disparities in Cardiovascular Disease Risk sponsored by @UABCardiology Honored to be invited My talk will be on ‘Race and cardiovascular risk. Is it genes or environment?’

Save these dates for #EpiLifestyle25! New Orleans is the place to be for insightful discussions, leading epidemiology and lifestyle science, and networking with colleagues old and new.

@Drlipid I have noticed increasing use of Lpa testing in patients referred to me in the last year. I think #s are improving @ArchnaBajajMD @DrSafarova @Drlipid

@dan_soffer Not surprised but still embarrassing, although UPHS likely better that elsewhere. How can a physician, especially a cardiologist, not know about Lp(a) in 2024?

Attitudes and Barriers to Lipoprotein(a) Testing: A Survey of Providers at the University of Pennsylvania Health System, JCL in press. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Attitudes and Barriers to Lipoprotein(a) Testing: A Survey of Providers at the University of Pennsylvania Health System. @dan_soffer authors.elsevier.com/a/1jn5T_hzJR10…

Real-world experience of inclisiran at UPenn, now in JCL: authors.elsevier.com/a/1jpv%7E6tb2E… @dan_soffer @MWilkinsonMD

Join us for Beyond the Basics: Approach to Lipoprotein(a) Management, a complimentary dinner program with CVI and PLAC! October 16, at the Loews Philadelphia Hotel. tinyurl.com/6ym2jve9

In this @medscapeCME, #CardioRheumatology experts Dr. Michael Garshick and Dr. Brittany Weber share insights on assessing inflammatory risk and the latest treatments to improve outcomes for patients at risk of cardiovascular events. @nyugrossman @RobMagyar @garshick @Bweber04

Now available @nationallipid @MarlysLPA @MBBoffa @Lpa_Doc @hillypaige2 @PennCVFellows @PennCardiology @ProfKausikRay @JohnKastelein @ArsenaultBenoit @Drlipid

Thanks Dr. Kulkarni for the opportunity. It’s always fun to write about lipids :)

📄#SourceSaturday: Our Practical Recommendations in the Management of CV Diseases Check out this easy breakdown! 🔗Download the infographic ow.ly/ZyaE50TnaFA #LipidXcellence #CholesterolMonth

We’re just 10 DAYS away from thought-provoking sessions and impactful discussion at the #FamilyHeartSummit24. Wave hi if we’ll see you there! 👋

I have had the pleasure of working with @TinaKReddy and team to highlight the importance of public health measures and team-based care in addressing the disproportionate burden of resistant hypertension in US Black adults. See our article here! link.springer.com/article/10.100…

Lipidaholics - just what you are all waiting for - another podcast of yours truly - this time interviewed by a pharmacist, Dr Tamara Ruggles - As usual I had a lot of fun - Visit and hopefully enjoy at https:// pharmacypodcastnetwork.podbean.com/e/the-lipid-lo… @nationallipid @society_eas @escardio @atherosociety @TheFHFoundation

Anne Langsted and I wrote a quick and comprehensive ABC on "Lipoprotein(a) and cardiovascular disease", just published in The Lancet: thelancet.com/journals/lance… As 1 in 5 have this the most common genetic cause of CVD, it is high time to measure in all at CVD risk. Treatment soon:

@nationallipid recently made recommendations to consider lipoprotein apheresis in certain patients with elevated Lp(a): sciencedirect.com/science/articl… @MarlysLPA @MBBoffa @kcferdmd @ErinMichos @DrSafarova @dan_soffer @PamTaubMD @CBallantyneMD @grsoffer @hsbhatia @DrMichaelShapir

Lp(a) is actionable today, & for some patients this includes treatment with lipoprotein apheresis link.springer.com/article/10.100… @MBBoffa @MarlysLPA @kcferdmd @ErinMichos @DrSafarova @nationallipid @ASPCardio @dan_soffer @CBallantyneMD @PamTaubMD @DrMichaelShapir @lipiddoc @UCSDHealth

@DudzLightLime @carolkirkpat3 @theproof @NutritionMadeS3 @Drlipid @DudzLightLime that is not correct at all. I would suggest reading the paper or waiting for the finished infographic (apologies for inadvertent release of unedited version which was taken down from site when we realized the mistake).

@carolkirkpat3 @theproof @dan_soffer @NutritionMadeS3 @Drlipid Thank you Carol 🙏 to be clear, NLA would not recommend pharmacological intervention for normal/low risk individuals unless ApoB >130 mg/dl? Ty Ty Ty for your insight 🙏

The National Lipid Association just issued a consensus recognizing ApoB as more precise than LDL-C and proposing specific therapeutic goals It´s only a matter of time before this becomes more widespread H/T @Drlipid lipid.org/sites/default/…

@theproof @carolkirkpat3 @NutritionMadeS3 @Drlipid that is why we need fabulous science communication experts like yourself to move the right message. Happy to discuss sometime why guidelines do not match expert care. This issue should be right in your wheelhouse

@dan_soffer @carolkirkpat3 @NutritionMadeS3 @Drlipid Makes sense! So technically the document is accurate. Perhaps not 'dummy' proof for folks like me who quickly saw it as target levels.